Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Common Equity (2023 - 2026)

Alto Neuroscience has reported Common Equity over the past 4 years, most recently at $243.4 million for Q1 2026.

  • Quarterly results put Common Equity at $243.4 million for Q1 2026, up 74.96% from a year ago — trailing twelve months through Mar 2026 was $243.4 million (up 74.96% YoY), and the annual figure for FY2025 was $151.1 million, changed 0.21%.
  • Common Equity reached $243.4 million in Q1 2026 per ANRO's latest filing, up from $151.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $243.4 million in Q1 2026 and bottomed at -$71.7 million in Q4 2023.
  • Median Common Equity over the past 4 years was $139.1 million (2025), compared with a mean of $94.4 million.
  • The largest annual shift saw Common Equity skyrocketed 526.99% in 2024 before it crashed 32.41% in 2025.
  • Over 4 years, Common Equity stood at -$71.7 million in 2023, then soared by 311.32% to $151.5 million in 2024, then fell by 0.21% to $151.1 million in 2025, then soared by 61.02% to $243.4 million in 2026.
  • Business Quant data shows Common Equity for ANRO at $243.4 million in Q1 2026, $151.1 million in Q4 2025, and $111.6 million in Q3 2025.